Top ▲

Mitogen-activated protein kinases (MAP kinases)

Overview

« Hide

MAP kinases (CMGC kinases) may be divided into three major families: ERK, JNK and p38 MAP kinases.

ERK may be activated by phosphorylation by the dual specificity mitogen-activated kinase kinases, MAP2K1 (Q02750, also known as MEK1) and MAP2K2 (P36507, also known as MEK2). The inhibitors PD98059 [1,3] and U0126 [4-5] act to inhibit these enzymes [2], and are used to inhibit ERK1 and ERK2.

JNK may be activated by phosphorylation by the dual specificity mitogen-activated kinase kinases, MAP2K4 (P45985, also known as JNKK1) and MAP2K7 (O14733, also known as JNKK2) .

p38 may be activated by phosphorylation by the dual specificity mitogen-activated kinase kinases, MAP2K3 (P46734, also known as MEK3) and MAP2K6 (P52564, also known as SAPKK3).

Subfamilies

Families that contain targets of relevance to immunopharmacology are highlighted in blue

The Kinome image shown here was obtained from Chartier et al. (2013, <a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3740139/figure/fig-4/' target='_blank'>Figure 4</a>) <a href='https://www.ncbi.nlm.nih.gov/pubmed/23940838' target='_blank'>https://www.ncbi.nlm.nih.gov/pubmed/23940838</a> and has been annotated to show the kinases that are targeted by currently approved kinase inhibitor drugs (last updated in April 2018).

References

Show »

How to cite this family page

Database page citation:

Mitogen-activated protein kinases (MAP kinases). Accessed on 22/10/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=288.

Concise Guide to PHARMACOLOGY citation:

Alexander SPH, Fabbro D, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators. (2017) The Concise Guide to PHARMACOLOGY 2017/18: Enzymes. Br J Pharmacol. 174 Suppl 1: S272-S359.